Induction of dendritic cell-mediated immune responses against HIV-1 by antigen-capturing nanospheres in mice
- PMID: 15778965
- DOI: 10.1002/jmv.20317
Induction of dendritic cell-mediated immune responses against HIV-1 by antigen-capturing nanospheres in mice
Abstract
Prophylactic vaccines, designed to elicit potent humoral and cellular immune responses to human immunodeficiency virus type 1 (HIV-1) antigens in mucosa, are the important approach to the protection of individuals against HIV-1 infection, since HIV-1 transmission is largely a result of sexual contact. In this study, a novel strategy has been developed to induce HIV-1-specific immune responses, which involves inactivated HIV-1-caputring concanavalin A (Con A)-immobilized nanospheres (HIV-NS) and their interaction with bone marrow (BM)-derived dendritic cells. HIV-NS were taken up by dendritic cells via cytoskeleton-dependent but mannose-binding site-independent phagocytosis. Serial stimulations to unprimed T-cells with HIV-1 gp120-capturing NS-pulsed dendritic cells could induce antigen-specific T-cell response. Intranasal administration of fluorescein isothiocyanate-labeled nanospheres (NS) in mice proved that the particles were taken up into pulmonary dendritic cells. Analysis of mice receiving intranasal immunizations with HIV-NS revealed that the mice efficiently induced the antibodies against HIV-1 in the genital tract and specific cytotoxic T-cells in the spleen. These results suggest that the use of HIV-1-NS may provide a novel and promising approach for the induction of humoral and cellular immune responses to HIV-1.
Copyright 2005 Wiley-Liss, Inc.
Similar articles
-
Mucosal immunization with inactivated HIV-1-capturing nanospheres induces a significant HIV-1-specific vaginal antibody response in mice.J Med Virol. 2003 Feb;69(2):163-72. doi: 10.1002/jmv.10279. J Med Virol. 2003. PMID: 12683403
-
Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques.J Med Virol. 2004 Jul;73(3):368-77. doi: 10.1002/jmv.20100. J Med Virol. 2004. PMID: 15170630
-
AIDS vaccine: Intranasal immunization using inactivated HIV-1-capturing core-corona type polymeric nanospheres.J Control Release. 2005 Dec 5;109(1-3):49-61. doi: 10.1016/j.jconrel.2005.09.014. Epub 2005 Oct 26. J Control Release. 2005. PMID: 16256237
-
Virus-like particles as HIV-1 vaccines.Rev Med Virol. 2005 Mar-Apr;15(2):75-88. doi: 10.1002/rmv.449. Rev Med Virol. 2005. PMID: 15484204 Review.
-
Humoral immune responses to the human immunodeficiency virus type-1 (HIV-1) in the genital tract compared to other mucosal sites.J Reprod Immunol. 2006 Dec;72(1-2):1-17. doi: 10.1016/j.jri.2006.05.006. J Reprod Immunol. 2006. Corrected and republished in: J Reprod Immunol. 2007 Feb;73(1):86-97. doi: 10.1016/j.jri.2007.01.006. PMID: 17095369 Corrected and republished. Review.
Cited by
-
Emerging nanotechnology approaches for HIV/AIDS treatment and prevention.Nanomedicine (Lond). 2010 Feb;5(2):269-85. doi: 10.2217/nnm.10.1. Nanomedicine (Lond). 2010. PMID: 20148638 Free PMC article. Review.
-
Induction of potent CD8+ T-cell responses by novel biodegradable nanoparticles carrying human immunodeficiency virus type 1 gp120.J Virol. 2007 Sep;81(18):10009-16. doi: 10.1128/JVI.00489-07. Epub 2007 Jul 3. J Virol. 2007. PMID: 17609261 Free PMC article.
-
A review of nanotechnological approaches for the prophylaxis of HIV/AIDS.Biomaterials. 2013 Aug;34(26):6202-28. doi: 10.1016/j.biomaterials.2013.05.012. Epub 2013 May 28. Biomaterials. 2013. PMID: 23726227 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous